Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833

Phase 1

Completed

Conditions: Breast Cancer
Cancer
Carcinoma, Renal Cell
Lymphoma
Ovarian Cancer

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT00001383

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Docetaxel
Drug: Capecitabine

First Posted Date: 2002-11-27

Last Posted Date: 2011-08-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 603

Registration Number: NCT00050167

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2002-11-15

Last Posted Date: 2009-01-09

Lead Sponsor: CASI Pharmaceuticals, Inc.

Registration Number: NCT00049790

Locations: 🇺🇸
Indiana Cancer Pavilion, Indiana University, Indianapolis, Indiana, United States

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Breast Neoplasms
Metastases, Neoplasm

First Posted Date: 2002-11-11

Last Posted Date: 2012-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00048893

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States